ReviewInternational journal of molecular sciences2022
Genetic Heterogeneity, Tumor Microenvironment and Immunotherapy in Triple-Negative Breast Cancer.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 1 synthesis or guideline pooled it, 103 citations in OpenAlex.
- Research on therapeutic clinical trials including immunotherapy in triple-negative breast cancer: a bibliometric analysis.Frontiers in oncology · 2024Pooled it
- Spatial habitat radiomics predicts tertiary lymphoid structure status and identifies an IDO1Journal for immunotherapy of cancer · 2026Article
- Structure-Function Regulation of Proteolytically Stable Amphiphilic Peptide-Based Soft Materials With Antimicrobial Efficacy Against Drug-Resistant Strains and Anticancer Activity in Triple-Negative Breast Cancer Cells.Chembiochem : a European journal of chemical biology · 2026Article
- Beyond chemotherapy: the evolving role of photodynamic therapy in triple-negative breast cancer.Medical oncology (Northwood, London, England) · 2026Review
- Engineering smart polymeric lipid nanoparticles for breast cancer: AI-guided formulation design, biological barriers, and translational constraints.Journal of nanobiotechnology · 2026Review
- Advancements in Immune Checkpoint-Based Immunotherapy for Triple-Negative Breast Cancer.Current issues in molecular biology · 2026Review
- Special Issue "Breast Cancer: From Pathophysiology to Novel Therapies".International journal of molecular sciences · 2026Article
- Hierarchical Targeting of TREM2Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- MRI-based habitat and peritumoral radiomics for predicting HER2 status in breast cancer: a multicenter study.Scientific reports · 2026Article
- TNBC Spatial Transcriptomic Analysis across Clinical States Reveals Subtype-Specific Networks and Immunosuppressive Niches.Cancer research communications · 2026Article
- Chemoresistance in gynecologic cancers: mechanistic insights and emerging platforms to overcome drug failure.Journal of ovarian research · 2026Review
- Exploring a specialized lactylation pattern to predict the prognosis and sensitivity of immunotherapy in breast cancer via machine learning.Breast cancer (Tokyo, Japan) · 2026Article
- Time-Dependent Loss of miR-548c-3p and Activation of E2F3/FOXM1 in Breast Cancer: In Vitro and TCGA-Based Evidence for a Post-Transcriptional Mechanism.International journal of molecular sciences · 2026Article
- Article
- New insight into the risk stratification and treatment priority of breast cancer: TMT scoring system.International journal of surgery (London, England) · 2026Article
- CMSS1 promoted CXCL8-CXCR1/2 pathway to accelerate the invasion and immune escape of triple-negative breast cancer.Journal of molecular histology · 2026Article
- An updated review on the role of extracellular vesicles in immune system modulation in breast cancer with special emphasis on immune checkpoint regulators.Frontiers in immunology · 2026Review
- Novel insights into triple-negative breast cancer heterogeneity, prognosis, and treatment response based on matrix stiffness: a combined single-Cell and transcriptome analysis.Frontiers in oncology · 2026Article
- The relationship between sarcopenia and breast cancer: mechanistic pathways and clinical relevance.Frontiers in cell and developmental biology · 2026Review
- Discrimination of Triple-Negative Breast Cancer: A Robust Clinical Baseline versus Multimodal Magnetic Resonance Imaging Integrated Models with Assessment of Generalizability.Breast cancer (Dove Medical Press) · 2026Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heterogeneity of triple-negative breast cancer is well known at clinical, histopathological, and molecular levels. Genomic instability and greater mutation rates, which may result in the creation of neoantigens and enhanced immunogenicity, are additional characteristics of this breast cancer type. Clinical outcome is poor due to early age of onset, high metastatic potential, and increased likelihood of distant recurrence. Consequently, efforts to elucidate molecular mechanisms of breast cancer development, progression, and metastatic spread have been initiated to improve treatment options and improve outcomes for these patients. The extremely complex and heterogeneous tumor immune microenvironment is made up of several cell types and commonly possesses disorganized gene expression. Altered signaling pathways are mainly associated with mutated genes including p53,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.